Study: NCT05099367

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Microdialysis, current induced vasodilation
Description: CIV will be applied over all microdialysis fibers: one perfused with saline, one perfused with a preferential COX-1 blocker; and one perfused with a preferential COX-2 blocker.~CIV will be applied over all fibers in the following conditions: one perfused with saline, one perfused with fluconazole and L-NMMA, and the last one perfused with lidocaine.Dialysate collection will be performed after each CIV: dermal PGI2 metabolite (6-ketoPGF1α) and other COX-dependent prostanoids or metabolite (e.g. 11-dehydroTXB2) will be collected in the dialysate fluid and quantified. One hour after the last condition, treprostinil will be perfused over all fibers.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Microdialysis, current induced vasodilation
Description: CIV will be applied over all microdialysis fibers: one perfused with saline, one perfused with a preferential COX-1 blocker; and one perfused with a preferential COX-2 blocker.~CIV will be applied over all fibers in the following conditions: one perfused with saline, one perfused with fluconazole and L-NMMA, and the last one perfused with lidocaine.Dialysate collection will be performed after each CIV: dermal PGI2 metabolite (6-ketoPGF1α) and other COX-dependent prostanoids or metabolite (e.g. 11-dehydroTXB2) will be collected in the dialysate fluid and quantified. One hour after the last condition, treprostinil will be perfused over all fibers.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Microdialysis, current induced vasodilation
Description: CIV will be applied over all microdialysis fibers: one perfused with saline, one perfused with a preferential COX-1 blocker; and one perfused with a preferential COX-2 blocker.~CIV will be applied over all fibers in the following conditions: one perfused with saline, one perfused with fluconazole and L-NMMA, and the last one perfused with lidocaine.Dialysate collection will be performed after each CIV: dermal PGI2 metabolite (6-ketoPGF1α) and other COX-dependent prostanoids or metabolite (e.g. 11-dehydroTXB2) will be collected in the dialysate fluid and quantified. One hour after the last condition, treprostinil will be perfused over all fibers.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy will be proposed. It will be performed on the internal superior calf (medial gastrocnemius), at a reasonable distance from the foot

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy will be proposed. It will be performed on the internal superior calf (medial gastrocnemius), at a reasonable distance from the foot

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy will be proposed. It will be performed on the internal superior calf (medial gastrocnemius), at a reasonable distance from the foot

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: peri-ulcerated skin biopsy
Description: Non-ulcerated skin from the peri-wound area will be collected. These patient will not undergo all the procedures included in this protocol.